Figure 1.
![Figure 1. Outcomes of TCRαβ/CD19-depleted haplo-HSCT. (A) NRM of the whole cohort of patients enrolled in the trial. (B) Cumulative incidence of relapse of the whole cohort of patients enrolled in the trial. (C) LFS of the whole cohort of patients enrolled in the trial. (D) LFS according to the disease type (ALL [continuous green line] vs AML [dotted red line]). E, events; N, number.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/130/5/10.1182_blood-2017-04-779769/4/blood779769f1.jpeg?Expires=1735821535&Signature=f1oNmfaTOmeDtXMI3ZG~p9mIgiblTKjzc1uZLexuASw~rCXl1t6i4MGdUQHpkZVtBUFnq4Jl6rXXCwZrEzpXKGseYnbsOAc2H-DG~005O2MiE4lYnTjl20fN2FoNgwqkrJm8ulf8JnXfQwtqlbK-8fwHzq-3qeO1ugD9aiKHPfrZ3-DzI-ile9fIyaxqCCKfFqitzSoY2v36glX8hz5C96I1AUugKB~y2gvhbiWc3MpGhspL7j~ZLA29ONBeZUo7o78qs3CC4I3w610MX0412trF5bEsSO0pj-glnvvm9hmvaNmfS9U-LtnV-DI-i9ZBt~t-ySD45oWa7cwm9eD9tw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Outcomes of TCRαβ/CD19-depleted haplo-HSCT. (A) NRM of the whole cohort of patients enrolled in the trial. (B) Cumulative incidence of relapse of the whole cohort of patients enrolled in the trial. (C) LFS of the whole cohort of patients enrolled in the trial. (D) LFS according to the disease type (ALL [continuous green line] vs AML [dotted red line]). E, events; N, number.
